Senior Technical Team
Dominique Bridon, PhD
Chief Technology Officer
Dr. Dominique Bridon brings 30 years of executive and scientific leadership experience to the Epivax Oncology team. Most recently, he was Chief Executive officer at Biodesy, a company specialized in the detection of conformational changes. He holds a Master of Science, Chemical Engineering and Polymer Sciences from Ecole Nationale Supérieure de Chimie and a PhD in Organic Chemistry from the University of Paris XI, ICSN, Orsay, France with Nobel Laureate Sir Derek H. R. Barton as Research Advisor.
Gary Steinberg, MD
Chief Medical Officer
Gary Steinberg, MD, specializes in urologic oncology. He has been instrumental in developing innovative surgical procedures for patients with bladder cancers. In addition, Dr. Steinberg’s research includes developing new treatments for urologic cancers, especially bladder cancer. He has performed over 2500 radical cystectomies and is a national leader in continent urinary tract reconstruction. He has been a national principal investigator, scientific advisor and protocol development advisor for multiple innovative clinical trials and translational research studies utilizing novel agents including oncolytic vaccines and immunotherapeutic agents. He has been a key advisor in clinical trial design, protocol development, study completion and analysis for patients with high risk non-muscle invasive bladder cancer.
Michael Princiotta, PhD
Michael Princiotta brings over 20 years experience in T cell immunology and antigen processing and presentation to Epivax Oncology. Most recently, he was Vice President of Research at Advaxis Immunotherapies where, as head of research, he oversaw the development of a personalized cancer vaccine from conception to Phase I clinical trial. Michael holds a Master of Science in Microbiology and Molecular Biology from the University of Central Florida and a PhD in Microbiology and Immunology from the University of Colorado Health Science Center in Denver Colorado.
Guilhem Richard, PhD
Lead Computational Immunologist
Guilhem Richard brings immunoinformatics expertise to the EpiVax Oncology team. He has been a Computational Immunologist for over 4 years at EpiVax, focusing on refining its immuno-oncology platform. He holds a Master of Engineering in Bioinformatics and Modeling from the National Institute of Applied Science (INSA) of Lyon, France, and a Ph.D. in Bioinformatics from Boston University.
Board of Directors
Daniel Adams, JD
Daniel Adams is the Executive Chairman and Co‐Founder of NextWaveBio, a next‐generation biotechnology enterprise developing safer, more affordable pharmaceuticals. Mr. Adams served as CEO then as the Executive Chairman of Protein Sciences Corporation, a leader in developing and manufacturing vaccines, therapeutics and diagnostics, including Flublok®, a patented, first in class recombinant influenza vaccine, that received licensure from FDA in 2013. The Company was acquired by Sanofi for approximately $750 million. Previously Dan founded and managed several biotechnology companies including Biogen that achieved a combined value of well in excess of $60 billion.